Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Exelixis
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06191796CT.gov Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Clear Cell Renal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ab521 (this asset) | Exelixis | P1 | CC · 43 |
| Everolimus | Peking University First Hospital | P2 | BB |
| Axitinib | University of California, San Francisco | P3 | B |
| Nivolumab | Exelixis | P2 | B |
| Pazopanib | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | P2 | B |
| Pembrolizumab | Sairopa B.V. | P2 | B |
| Zanzalintinib | Kelly Fitzgerald, MD | P2 | B |
| Toripalimab | RenJi Hospital | P2 | B |
| Modified Vaccinia Virus Ankara-5T4 Antigen | Oxford BioMedica | P3 | B |
+31 more in the Clear Cell Renal Carcinoma cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ab521 in Clear Cell Renal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ab521-clear-cell-renal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →